-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2024-514135-17-00
5
2024-11-28
Immunoglobulin A Nephropathy
-
2023-505605-16-00
7
2024-04-24
Metastatic Clear Cell Renal Cell Carcinoma (ccRCC) or papillary renal
-
2022-501890-38-00
4
2024-02-16
acute ischemic stroke
-
2022-501220-14-00
4
2023-10-17
epithelial ovarian, primary peritoneal, or fallopian tube cancer
-
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
-
2022-500544-38-00
5
2023-06-05
Advanced Breast Cancer
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2024-520443-16-00
5
2026-05-04
Overweight or obesity, and obstructive sleep apnoea treated with posit
-
2024-520442-36-00
5
2026-04-30
Overweight or obesity, and obstructive sleep apnoea not treated with p
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2025-520972-24-00
5
2026-04-08
Chronic Obstructive Pulmonary Disease (COPD)
-
2025-522012-16-00
4
2026-03-13
Breast Cancer
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)
-
2024-518465-10-00
4
2025-12-12
Multiple Autoimmune Glomerular Diseases
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-518521-14-00
6
2025-10-17
Critical condition
-
2024-519883-42-00
5
2025-10-08
Non-small cell lung cancer
-
2024-519445-29-00
1
2025-10-02
Solid Tumors
-
2024-517383-28-00
5
2025-07-21
Acute haemorrhagic stroke